Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects

NCT01708590 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

661

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Psoriasis

Interventions

DRUG: 210 mg brodalumab
DRUG: 140 mg brodalumab
DRUG: placebo

Sponsor

Bausch Health Americas, Inc.